investorscraft@gmail.com

Investor's Craft

S&P 500 Health CareS&P 500 EnergyS&P 500 Information Tech.S&P 500 Communic. ServicesS&P 500 Consumer Discret.S&P 500 Consumer StaplesS&P 500 IndustrialsS&P 500 Materials
IntroductionThe concept of valuationRevenue and revenue growthVariable costsFixed costsProduction assets

Intrinsic value of Catalyst Pharmaceuticals, Inc. (CPRX)

Previous Close$15.52
Intrinsic Value$242.32
Upside potential  +1,461%
Previous Close
$15.52
Intrinsic Value
$242.32
Potential        
+1,461%

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh242.32 242.32

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-09-30.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %18.3NaN
Revenue, $141NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m88NaN
Operating income, $m52NaN
EBITDA, $m53NaN
Interest expense (income), $mNaN
Earnings before tax, $m53NaN
Tax expense, $m13NaN
Net income, $m39NaN

BALANCE SHEET

Cash and short-term investments, $m191NaN
Total assets, $m238NaN
Adjusted assets (=assets-cash), $m47NaN
Average production assets, $m203NaN
Working capital, $m183NaN
Total debt, $m4NaN
Total liabilities, $m31NaN
Total equity, $m207NaN
Debt-to-equity ratio0.020NaN
Adjusted equity ratio0.341NaN

CASH FLOW

Net income, $m39NaN
Depreciation, amort., depletion, $m0NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m60NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-1NaN
Free cash flow, $m61NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m183
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount